Corvus Pharmaceuticals, Inc.
(NASDAQ : CRVS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.68%145.650.7%$932.14m
PFEPfizer Inc. 0.84%36.060.9%$892.16m
MRKMerck & Co., Inc. -0.24%82.950.7%$692.55m
ABBVAbbVie, Inc. 0.35%86.211.9%$677.02m
BMYBristol-Myers Squibb Co. 2.15%59.501.0%$637.89m
LLYEli Lilly & Co. 0.97%150.261.1%$561.78m
AZNAstraZeneca Plc 2.47%55.511.2%$257.73m
NVSNovartis AG 0.96%87.130.2%$163.92m
GSKGlaxoSmithKline Plc 1.12%37.800.2%$109.18m
PRNBPrincipia Biopharma, Inc. 0.10%100.050.0%$86.76m
NVONovo Nordisk A/S 1.13%69.040.1%$57.64m
RGENRepligen Corp. 3.12%144.307.1%$49.54m
SNYSanofi -0.02%50.780.2%$49.00m
RPRXRoyalty Pharma Plc -0.40%40.070.2%$47.01m
OPKOPKO Health, Inc. 4.89%3.2211.2%$43.56m

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.